Back to results
US 2002/0165160 A1Published application
Angiogenically effective unit dose of FGF and method of administering
AssigneeChiron Corporation
InventorMartha J. Whitehouse
Life of this patent
Estimating the term…
Loading patent…
Loading patent…
AssigneeChiron Corporation
InventorMartha J. Whitehouse
Estimating the term…
The present invention has multiple aspects. In particular, in one aspect, the present invention is directed to a unit dose comprising 0.2 μg/kg to 36 μg/kg of a recombinant FGF or an angiogenically active fragment or mutein thereof. In another aspect, the present invention is directed to a pharmaceutical composition comprising an angiogenically effective dose of an FGF or an angiogenically active fragment or mutein thereof, and a pharmaceutically acceptable carrier. Typically, the angiogenically effective dose comprises 0.2 μg/kg to 36 μg/kg of an FGF of any one of SEQ ID NOS: 1-3, 5, 8-10, or 12-14 or an angiogenically active fragment or mutein thereof. In yet another aspect, the present invention is directed to a method for treating a human patient for coronary artery disease, comprising administering into at least one coronary vessel of a human patient in need of treatment for coronary artery disease a safe and angiogenically effective dose of a recombinant FGF of any one of SEQ ID NOS: 1-3, 5, 8-10, or 12-14, or an angiogenically active fragment or mutein thereof.
A method for treating a human patient for coronary artery disease, comprising administering into one or more coronary vessels in a human patient in need of treatment for coronary artery disease a therapeutically effective amount of an angiogenically active fragment of a recombinant fibroblast growth factor (FGF) having the sequence set forth in SEQ ID NO:
A method for treating a human patient for coronary artery disease, comprising administering into one or more coronary vessels in a human patient in need of treatment for coronary artery disease a therapeutically effective amount of an angiogenically active mutein of a recombinant fibroblast growth factor (FGF) having the sequence set forth in SEQ ID NO:
A method for inducing angiogenesis in the heart of a patient, comprising administering into one or more coronary vessels of a human patient in need of coronary angiogenesis a therapeutically effective amount of a recombinant fibroblast growth factor (FGF) having the sequence set forth in SEQ ID NO:
A unit dose of a fibroblast growth factor (FGF), comprising about 0.008 mg to about 6.1 mg of an FGF having the amino acid sequence of SEQ ID NO:
A pharmaceutical composition comprising (i) a therapeutically effective amount of a fibroblast growth factor (FGF) having the sequence of SEQ ID NO:
Dependencies are inferred from the claim text.